Supplementary Figure 3 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis | Synapse
July 15, 2025
Supplementary Figure 3 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis
Puntos clave
Eltanexor, an xpo1 inhibitor, effectively reduces tumor growth in colorectal cancer xenograft models.
The treatment demonstrates modulation of the wnt/beta-catenin signaling pathway crucial for tumorigenesis.
Research focused on the HCT116 xenograft model to assess the therapy's impact on growth rates.
These findings suggest that eltanexor could offer a novel approach in managing colorectal cancer.